News

As I prepare for my Thanksgiving meal, I’m struck by the number of CPT codes that physicians may have to use this season.

In months, the US may have its first marketed peanut immunotherapies. How will pediatric patient management change?

Results of the ESETT trial are revealing there is little difference in the effectiveness or safety profiles of three anti-seizure treatments for patients with a severe form epilepsy.

An analysis of mepolizumab use shows fewer than 1% of prescribed patients are likely to use biologics concomitantly.

Discussing why initiatives and policy changes in the fight against obesity and diabetes have been perceived as less successful than those against smoking and educating on cardiovascular diseases.

How PTSD care can be, and should be, individualized for particular patient needs.

Evaluating the impact of DAPA-HF and other recent data that have changed the way cardiologists view the potential uses of SGLT2 inhibitors in patients with or without diabetes.

Discussing how new information released in 2019 has impacted the way cardiologists view aspirin use for primary and secondary prevention of cardiovascular events.

Toujeo has been given an added indication which allows its use for blood sugar control in patients as young as 6 years old.

A new study of more than 100,000 patients in the UK found patients living in areas with greater amounts of air pollution were at an increased risk of glaucoma.

The deoxygenated sickle hemoglobin polymerization inhibitor was granted Accelerated Approval designation for the burdensome rare disease.

Novartis AG is set to acquire The Medicines Company in a $9.7 billion deal that is set to be completed in the first quarter of 2020.

In a study based in Finland, investigators link different types of oral antibiotics to an increased risk of Parkinson disease.

Investigators examine how different supplementation impacts kidney function in patients with type 2 diabetes.

Patient demographics influence difference symptoms, progression, and benefits of care.

How to weigh the 5 agents from the drug class, which have each shown differing benefit in younger patients.

A new analysis from the World Health Organization has found 80% of children across 146 countries, including the United States and Canada, fail to meet the recommended guideline of 1 hour of activity per day.

New data suggests that bipolar disorder 1 is linked with longer sleep durations, while bipolar disorder II is tied to insomnia.

Though vaccination rates are decreasing in children and adolescents overall, it is not due to consideration of previous season's successes or failures.

Results of the CITU study are revealing more about the different impacts e-cigarette and tobacco use has on a patient's lipid profile.

The once-daily oral therapy is recommended at a 200 mg dose, following titration.

A new analysis from the University of Minnesota has found many patients with and without an indication for regular low dose aspirin use are under or overusing the medication.

The approval allows Medtronic to move forward with the IN.PACT AV balloon to treat failing arteriovenous access for patients with end-stage renal disease undergoing dialysis.

The new approval grants BD the ability to move forward with a new device aimed at repairing abdominal hernias.

The therapy was shown in a 94-patient trial to reduce porphyria attacks by 70% versus placebo.

The FDA gives a green light to MiSight, a single use, contact lens to slow the progression of nearsightedness in children.

Crizanlizumab is the first ever drug approved to reduce vaso-occlusive crises in patients with the rare blood disease.

In the pivotal assessment, three-quarters of patients who received cefiderocol had resolution of symptoms and eradication of the bacteria 1 week after completing treatment, versus 54.6% of patients who received an alternative antibiotic.